U biosensors, and related U-sensing genetic molecular components, genetic circuits, compositions, methods and systems are described, which in several embodiments can be used to detect and/or neutralize uranium and in particular bioavailable U.

U biosensors, and related U-sensing genetic molecular components, genetic circuits, compositions, methods and systems are described, which in several embodiments can be used to detect and/or neutralize uranium and in particular bioavailable U.

Methods of, inter alia, detecting the presence of one or more analytes in one or more query samples include providing one or more sensor that each include biomolecules disposed on a functionalized surface of one or more giant magnetoresistance (GMR) sensors. Modes of operation remove or add magnetic beads from the vicinity of sensor surfaces by interactions with the biomolecules. The methods feature, inter alia, detecting the presence of one or more analytes in one or more query samples by measuring magnetoresistance change of the one or more GMR sensors based on determining magnetoresistance before and after passing magnetic particles over the one or more sensors.

Methods of, inter alia, detecting the presence of one or more analytes in one or more query samples include providing one or more sensor that each include biomolecules disposed on a functionalized surface of one or more giant magnetoresistance (GMR) sensors. Modes of operation remove or add magnetic beads from the vicinity of sensor surfaces by interactions with the biomolecules. The methods feature, inter alia, detecting the presence of one or more analytes in one or more query samples by measuring magnetoresistance change of the one or more GMR sensors based on determining magnetoresistance before and after passing magnetic particles over the one or more sensors.

Disclosed herein are automated processes and systems for determining an underlying cause of anemia. Also disclosed herein are processes and systems for determining an underlying cause of microcytic anemia, normocytic anemia, and macrocytic anemia. Additionally disclosed herein are methods of treating the underlying cause of anemia in an individual in need thereof.

This disclosure relates to methods of measuring copper concentrations in biological samples. More particularly, this disclosure relates to methods of measuring non-ceruloplasmin-bound copper concentrations and/or labile-bound copper concentrations in biological samples. Such methods are particularly useful in management and treatment of metabolism-associated diseases or disorders.

This disclosure relates to methods of measuring copper concentrations in biological samples. More particularly, this disclosure relates to methods of measuring non-ceruloplasmin-bound copper concentrations and/or labile-bound copper concentrations in biological samples. Such methods are particularly useful in management and treatment of metabolism-associated diseases or disorders.

Methods for identifying premature infants at risk for developing bronchopulmonary dysplasia and/or most likely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia (BPD). Methods for treating premature infants identified as at risk and/or likely to benefit are provided. also provided are methods for identifying premature infants that are not at risk for developing bronchopulmonary dysplasia and/or unlikely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia, and methods for avoiding risks of toxicity and undesirable side effects associated with inhaled nitric oxide therapy comprising administering only non-iNO treatment modalities to these infants.

Methods for identifying premature infants at risk for developing bronchopulmonary dysplasia and/or most likely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia (BPD). Methods for treating premature infants identified as at risk and/or likely to benefit are provided. also provided are methods for identifying premature infants that are not at risk for developing bronchopulmonary dysplasia and/or unlikely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia, and methods for avoiding risks of toxicity and undesirable side effects associated with inhaled nitric oxide therapy comprising administering only non-iNO treatment modalities to these infants.

A medical, dental, or veterinary device with a use indicator includes a proximal end and a distal end configured to interact with a human or animal subject, the distal end including a use indication portion, wherein the use indication portion includes a reactive agent to react with a foreign substance to exhibit a visible change in appearance of the reactive agent to indicate to a veterinary, dental, or medical professional that the device had been previously used and must be sterilized or disposed.